메뉴 건너뛰기




Volumn 69, Issue 1, 2011, Pages 56-63

Botulinum toxin type-A effect as a preemptive treatment in a model of acute trigeminal pain: A pre-clinical double-blind and placebo-controlled study;Toxina botulínica do tipo-A no tratamento preemptivo da dor trigeminal aguda: Estudo pré-clínico duplo cego placebo controlado

Author keywords

Antinociceptive effect; Botulinum neurotoxin type A; Orofacial pain; Preemptive treatment

Indexed keywords

BOTULINUM TOXIN A;

EID: 79952332075     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2011000100012     Document Type: Article
Times cited : (10)

References (24)
  • 1
    • 79952318986 scopus 로고    scopus 로고
    • Clinical concepts and commentary
    • Weiskopf RB. Clinical concepts and commentary. Anesthesiology 2000;93: 1138-1143.
    • (2000) Anesthesiology , vol.93 , pp. 1138-1143
    • Weiskopf, R.B.1
  • 2
    • 0027166359 scopus 로고
    • Preemptive analgesia: Treating postoperative pain by preventing the establishment of central sensitization
    • Woolf CJ, Chong MS. Preemptive analgesia: treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 1993; 77:362-379.
    • (1993) Anesth Analg , vol.77 , pp. 362-379
    • Woolf, C.J.1    Chong, M.S.2
  • 3
    • 33644787497 scopus 로고    scopus 로고
    • The challenge of preemptive analgesia
    • Aida S. The challenge of preemptive analgesia. Pain 2005;13:1-4.
    • (2005) Pain , vol.13 , pp. 1-4
    • Aida, S.1
  • 4
    • 34249789001 scopus 로고    scopus 로고
    • Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo
    • Hou YP, Zhang YP, Song YF, Zhu CM, Wang YC, Xie GL. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo. Can J Physiol Pharmacol 2007;85:209-214.
    • (2007) Can J Physiol Pharmacol , vol.85 , pp. 209-214
    • Hou, Y.P.1    Zhang, Y.P.2    Song, Y.F.3    Zhu, C.M.4    Wang, Y.C.5    Xie, G.L.6
  • 5
    • 34548567008 scopus 로고    scopus 로고
    • Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their antinociceptive potential
    • Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their antinociceptive potential. J Cell Sci 2007;120:2864-2874.
    • (2007) J Cell Sci , vol.120 , pp. 2864-2874
    • Meng, J.1    Wang, J.2    Lawrence, G.3    Dolly, J.O.4
  • 6
    • 44049104774 scopus 로고    scopus 로고
    • Glutamate uptake and release by astrocytes are enhanced by Clostridium botulinum C3 protein
    • Höltje M, Hofmann F, Lux R, Veh RW, Just I, Ahnert-Hilger G. Glutamate uptake and release by astrocytes are enhanced by Clostridium botulinum C3 protein. J Biol Chem 2008;283:9289-9299.
    • (2008) J Biol Chem , vol.283 , pp. 9289-9299
    • Höltje, M.1    Hofmann, F.2    Lux, R.3    Veh, R.W.4    Just, I.5    Ahnert-Hilger, G.6
  • 7
    • 34249742661 scopus 로고    scopus 로고
    • Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin
    • Tugnoli V, Capone JG, Eleopra R, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 2007;130:76-83.
    • (2007) Pain , vol.130 , pp. 76-83
    • Tugnoli, V.1    Capone, J.G.2    Eleopra, R.3
  • 8
    • 0019619833 scopus 로고
    • The origin, structure, and pharmacological activity of botulinum toxin
    • Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155-188.
    • (1981) Pharmacol Rev , vol.33 , pp. 155-188
    • Simpson, L.L.1
  • 9
    • 0034926291 scopus 로고    scopus 로고
    • The vanilloid receptor: A molecular gateway to the pain pathway
    • Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001;24:487-517.
    • (2001) Annu Rev Neurosci , vol.24 , pp. 487-517
    • Caterina, M.J.1    Julius, D.2
  • 10
    • 0037179755 scopus 로고    scopus 로고
    • p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia
    • Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002;36:57-68.
    • (2002) Neuron , vol.36 , pp. 57-68
    • Ji, R.R.1    Samad, T.A.2    Jin, S.X.3    Schmoll, R.4    Woolf, C.J.5
  • 11
    • 0037435881 scopus 로고    scopus 로고
    • Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons
    • Amaya F, Oh-hashi K, Naruse Y, et al. Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons. Brain Res 2003;963:190-196.
    • (2003) Brain Res , vol.963 , pp. 190-196
    • Amaya, F.1    Oh-hashi, K.2    Naruse, Y.3
  • 12
    • 0031563769 scopus 로고    scopus 로고
    • Microinjections of muscimol into lateral superior colliculus disrupt orienting and oral movements in the formalin model of pain
    • Wang S, Redgrave P. Microinjections of muscimol into lateral superior colliculus disrupt orienting and oral movements in the formalin model of pain. Neuroscience 1997;81:967-988.
    • (1997) Neuroscience , vol.81 , pp. 967-988
    • Wang, S.1    Redgrave, P.2
  • 13
    • 9644279795 scopus 로고    scopus 로고
    • Descending control of persistent pain: Inhibitory or facilitatory?
    • Vanegas H, Schaible HG. Descending control of persistent pain: inhibitory or facilitatory? Brain Res Rev 2004;46:295-309.
    • (2004) Brain Res Rev , vol.46 , pp. 295-309
    • Vanegas, H.1    Schaible, H.G.2
  • 14
    • 2942604988 scopus 로고    scopus 로고
    • Clinical presentation and management of antibody-induced failure of botulinum toxin therapy
    • Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004;19(Suppl 8):S92-S100.
    • (2004) Mov Disord , vol.19 , Issue.SUPPL 8
    • Dressler, D.1
  • 15
    • 33645855860 scopus 로고    scopus 로고
    • Botulinum neurotoxins and formalin-induced pain: Central vs. peripheral effects in mice
    • Luvisetto S, Marinelli S, Lucchetti F, et al. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res 2006;1082: 124-131.
    • (2006) Brain Res , vol.1082 , pp. 124-131
    • Luvisetto, S.1    Marinelli, S.2    Lucchetti, F.3
  • 16
    • 26444469528 scopus 로고    scopus 로고
    • Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A
    • Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. NeuroToxicol 2005;26:785-793.
    • (2005) NeuroToxicol , vol.26 , pp. 785-793
    • Aoki, K.R.1
  • 17
    • 0346094286 scopus 로고    scopus 로고
    • Subcutaneous administration of botulinum toxin A reduces formalin-induced pain
    • Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-133.
    • (2004) Pain , vol.107 , pp. 125-133
    • Cui, M.1    Khanijou, S.2    Rubino, J.3    Aoki, K.R.4
  • 19
    • 33749069285 scopus 로고    scopus 로고
    • A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis
    • BoNTA-024- 026-036 Study Group
    • Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R, BoNTA-024- 026-036 Study Group. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006;7:688-696.
    • (2006) J Pain , vol.7 , pp. 688-696
    • Elkind, A.H.1    O'Carroll, P.2    Blumenfeld, A.3    DeGryse, R.4    Dimitrova, R.5
  • 20
    • 34249797267 scopus 로고    scopus 로고
    • A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches
    • European BoNTA Headache Study Group
    • Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C, European BoNTA Headache Study Group. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007;27:492-503.
    • (2007) Cephalalgia , vol.27 , pp. 492-503
    • Relja, M.1    Poole, A.C.2    Schoenen, J.3    Pascual, J.4    Lei, X.5    Thompson, C.6
  • 21
    • 33846136926 scopus 로고    scopus 로고
    • Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: A five-year long experience
    • Farinelli I, Coloprisco G, De Filippis S, Martelletti P. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. J Headache Pain 2006;7:407-412.
    • (2006) J Headache Pain , vol.7 , pp. 407-412
    • Farinelli, I.1    Coloprisco, G.2    de Filippis, S.3    Martelletti, P.4
  • 22
    • 34248372532 scopus 로고    scopus 로고
    • Botulinum toxin type A in chronic migraine
    • Freitag FG. Botulinum toxin type A in chronic migraine. Expert Rev Neurother 2007;7:463-470.
    • (2007) Expert Rev Neurother , vol.7 , pp. 463-470
    • Freitag, F.G.1
  • 23
    • 54849435847 scopus 로고    scopus 로고
    • Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain
    • Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008; 64:274-283.
    • (2008) Ann Neurol , vol.64 , pp. 274-283
    • Ranoux, D.1    Attal, N.2    Morain, F.3    Bouhassira, D.4
  • 24
    • 67549127798 scopus 로고    scopus 로고
    • Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial
    • Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009;72:1473-1478.
    • (2009) Neurology , vol.72 , pp. 1473-1478
    • Yuan, R.Y.1    Sheu, J.J.2    Yu, J.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.